

PRESS RELEASE

HRA PHARMA AND PREGLEM ANNOUNCE SUCCESSFUL COMPLETION OF PHASE IIB FOR ULIPRISTAL ACETATE FOR THE TREATMENT OF UTERINE FIBROIDS

- *Results fully support the design of PregLem's ongoing Phase III program*
- *First in class product developed to treat uterine fibroids*

Paris, France and Geneva, Switzerland – 11 May, 2009: HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, and PregLem, the Swiss biopharmaceutical company specializing in women's reproductive medicine, today announced successful completion of the Phase Iib study of the compound ulipristal acetate for the treatment of uterine fibroids. The protocol was a follow-on to the recently-reported Phase Ila trial which demonstrated in a placebo-controlled design that ulipristal acetate is effective in rapidly controlling bleeding and reducing fibroid volume in women with symptomatic uterine fibroids (*Obstet & Gynecol* 2008;111(5):1129-36).

Ulipristal acetate (also known as CDB-2914 and PGL4001) is a first-in-class, orally active selective progesterone receptor modulator which reversibly blocks the progesterone receptors in target tissues. The phase Iib trial was a double-blind, placebo-controlled, dose finding study of 40 patients with symptomatic uterine fibroids. Ulipristal acetate or a matching placebo was administered for 12 weeks. The primary outcome measures were shrinkage of fibroids and patient quality of life. The trial was conducted by the US National Institutes of Health (NIH) under IND and the leadership of Dr Lynnette Nieman.

Ernest Loumaye, CEO of PregLem, commented:

"PGL4001 is the first potential medical treatment for uterine fibroids that rapidly controls the bleeding and effectively reduces the size of fibroids. We are pleased to observe the excellent efficacy of PGL4001 in quickly and sustainably controlling the symptoms related to fibroids. Our Phase III programme which consists of two separate parallel, randomised trials is ongoing (called PEARL I&II). It involves 540 patients in 14 countries, and we remain confident to deliver results by mid 2010."

Erin Gainer, CEO of HRA Pharma, commented:

“Thanks to our valued collaboration with the NIH and PregLem, ulipristal acetate is well on its way to realizing its potential as a promising new treatment for women who suffer from uterine fibroids. We are very pleased to have reached yet another milestone with successful completion of the PhIIb study and are looking forward to the results of PregLem’s ongoing PhIII programme.”

Uterine fibroids affect approximately 40% of women between the ages of 35 and 55, including 24 million women in Europe. The most common symptom is excessive uterine bleeding which may lead to anemia. It significantly impairs the quality of life for many women, leading in numerous cases to a hysterectomy. There are no effective, well tolerated medical treatments available.

Dr Nieman will review the evidence for clinical effectiveness of ulipristal acetate for the treatment of uterine fibroids at the annual congress of the European Society of Gynecology in Rome (10 – 13 September 2009).

End

For further information please contact:

Media Contact:

Christina Aplington
Ballou PR for HRA Pharma
+33 (0)1 4222 2410
christina@balloupr.com

Mary Clark / Olivia Tomlin
Capital MS&L for PregLem
Tel: +44 (0) 207 307 5330
Firstname.lastname@capitalmsl.com

Notes to Editors:

About HRA Pharma

HRA Pharma is an emerging, privately-held European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses innovative marketing solutions and socially-conscious programs, such as contraception education in developing countries, to promote

healthy management of drugs and diseases. A pioneer in emergency contraception, its product NorLevo was the first emergency contraceptive based on one type of progesterone to be approved for sale by health authorities.

Headquartered in Paris, France and with offices in Bochum, Germany, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe.

Ulipristal acetate is the leading candidate in HRA Pharma's pipeline. HRA is working in collaboration with multiple partners to develop ulipristal acetate for various indications.

Visit www.hra-pharma.com for more information.

About PregLem

PregLem is a Swiss speciality biopharmaceutical company, dedicated to the development and commercialization of a new class of drugs for women's reproductive health conditions. The company currently has four products in clinical and pre-clinical development.

PregLem has an experienced senior management team, with a proven track record in developing, registering and commercializing reproductive health products. The Company is backed by a blue chip investor base.

PregLem in-licensed ulipristal acetate from HRA Pharma to develop and commercialize it for the treatment of uterine myoma (fibroids) in doses of 5 and 10 mg. HRA recently obtained a positive CHMP recommendation for approval of ulipristal acetate in emergency contraception, a significant step towards de-risking the registration of PregLem's PGL4001. (see March 2009 press release on www.preglem.com).

Uterine Myoma

Current treatment options for uterine myoma remain sub-optimal. The market is dominated by invasive surgeries and there are no well tolerated medical treatments available. Surgical treatments can result in regrowth of tumours or lost fertility. Hormone therapy - GnRH agonists – are limited to 3-6 months treatment cycles and have major side effects such as bone density loss and menopausal symptoms. NSAIDs do not control the disease progression.

Information about PregLem-Sponsored Clinical Trials:

PregLem is committed to providing information about clinical trials sponsored by the Company. We have registered our company-sponsored ongoing Phase III clinical trials on the National Institutes of Health's (NIH) web site (www.clinicaltrials.gov).